SLC5A2 and hydrops fetalis: As a result, treatment with SGLT2 inhibitors in patients with DM II increased to 12% in 2018 in the Swedish HF registry [44] and was upgraded to a class 1A indication for patients with HFmrEF in 2023 [45].